Non-Hodgkin's lymphoma vaccine - XEME Biopharma

Drug Profile

Non-Hodgkin's lymphoma vaccine - XEME Biopharma

Alternative Names: B-cell lymphoma vaccine - XEME Biopharma; Follicular lymphoma vaccine - XEME Biopharma; Oncoquest-L; Oncoquest-L vaccine

Latest Information Update: 13 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator XEME Biopharma
  • Class Cancer vaccines
  • Mechanism of Action Cytotoxic T lymphocyte stimulants; Natural killer cell stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase I Non-Hodgkin's lymphoma

Most Recent Events

  • 09 Mar 2018 Cascadian Therapeutics has been acquired by Seattle Genetics
  • 31 Mar 2017 XEME Biopharma's Non-Hodgkin's-lymphoma-vaccine is still at phase I development stage in USA (SC) (Xeme Biopharma pipeline, March 2017).
  • 08 Jun 2016 Oncothyreon is now called Cascadian Therapeutics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top